Core Viewpoint - The article highlights the participation of Jiangsu Huacheng Biotechnology Co., Ltd. in the 2026 DT New Leaf Award, focusing on its innovative bio-based blue pigment and green dyeing solutions aimed at promoting sustainable practices in the textile industry [2][13]. Group 1: Company Overview - Jiangsu Huacheng Biotechnology Co., Ltd. was established in 2024, focusing on synthetic biology research and product commercialization, particularly in bio-based materials and biochemicals for pharmaceuticals, cosmetics, food, and health products [3]. - The company aims to drive industrial upgrades through technological innovation, emphasizing large-scale bio-manufacturing of food colorants, chemical dyes, and functional food ingredients [3]. Group 2: Bio-based Blue Pigment - The bio-based blue pigment is produced using synthetic biology techniques, utilizing engineered microorganisms as "cell factories" for efficient fermentation [4]. - Compared to chemical dyes, bio-based dyes are natural, non-toxic, and exhibit excellent antibacterial and anti-yellowing properties, with lower damage to high-end fabrics like silk and wool [4][10]. - The production process avoids traditional petroleum-based methods, reducing harmful substance generation and wastewater treatment costs, while achieving USDA bio-based product certification [8][10]. Group 3: Green Dyeing Solutions - Traditional chemical dyes pose significant health and environmental risks, leading to complex pollution issues in the textile industry [9]. - Huacheng's approach involves replacing chemical dyes with bio-based alternatives, providing scalable clean dyeing solutions that align with national environmental goals [9]. - The innovative process utilizes renewable carbon sources and mild fermentation conditions, significantly lowering wastewater chemical oxygen demand and overall energy consumption [9]. Group 4: Awards and Recognition - The DT New Leaf Award features four categories: Innovation Material Award, Innovation Application Award, Most Commercially Valuable Award, and Innovative Industry Solution Award, with the first round of applications closing on February 10, 2026 [5][13]. - Huacheng's participation in the award reflects its commitment to sustainable practices and innovation in the bio-based industry [2][13].

Core Viewpoint - The article discusses the successful development of a high-throughput screening system based on Surface-Enhanced Raman Spectroscopy (SERS) by Professor Wang Dan's team at Chongqing University, which allows for real-time, label-free analysis of bacterial metabolites within microdroplets, providing an efficient and sustainable technology for green biomanufacturing [2][4]. Group 1: High-Throughput Screening Platform - The RH-RMSS platform utilizes SERS technology to directly detect metabolite concentrations without the need for cell staining or labeling, processing 180 microdroplets per second, significantly faster than traditional methods [4]. - The platform successfully screened high-yield strains for various organic acids, achieving yields of 1.61 times, 1.52 times, and 1.81 times that of the original strains for succinic acid (SA), D-lactic acid (D-PLA), and acrylic acid (AA), respectively [4]. - The system reveals key enzyme mutation mechanisms and implements multi-level metabolic optimization, achieving a maximum succinic acid yield of 138.92 g/L using optimized strains [4]. Group 2: System Validation and Performance - The RH-RMSS system demonstrated high accuracy (>98%) and efficiency in screening, effectively enriching high-yield strains from a large pool of mutants [10]. - The system's ability to accurately quantify organic acids within individual microdroplets was validated, establishing its reliability as a high-throughput screening tool [8]. - The research successfully transitioned from microdroplet screening to large-scale fermentation verification, showcasing the engineered strains' capability to utilize non-food biomass as a carbon source for succinic acid production [15]. Group 3: Mechanistic Insights and Optimization Strategies - The D210G mutation was shown to enhance the catalytic efficiency of the phosphoenolpyruvate carboxylase (PEPC) enzyme, which is crucial for achieving high succinic acid yields [11]. - The study highlights the synergistic effects of neutralizing agent optimization, RBS sequence optimization, and adaptive evolution on improving succinic acid production [14]. - The RH-RMSS platform is presented as a versatile tool adaptable for screening high-yield strains for various organic acids and other metabolites with characteristic Raman signals [18].

Core Viewpoint - The "2026 DT New Leaf Award" is a global and comprehensive award focused on innovation in the bio-based sector, aimed at discovering, showcasing, and recognizing outstanding products and companies in the bio-based industry [2]. Group 1: Award Overview - The award symbolizes vitality and sustainable innovation, with the goal of uncovering pioneering forces in the bio-based industry that utilize renewable biomass and green technologies to drive low-carbon development [2]. - Over 30 representative companies from the bio-based industry are participating in the "2026 DT New Leaf Award" evaluation, with the first batch of participating companies announced [2]. Group 2: Participating Companies and Products - Wanhua Chemical Group Co., Ltd. is recognized as a leading global chemical new materials enterprise, participating with its low-carbon PCDL product, which is a versatile polyol used for high-end polyurethane materials [3]. - Leaf Bio, a global leader in bio-based aromatic materials, focuses on the development and production of furan-based materials, with core products FDCA and PEF being recognized as potential bio-based platform compounds [4]. - Henan Qiye Technology Development Co., Ltd. is the world's first company to produce non-food cellulose crystalline glucose in bulk, showcasing its innovative production techniques [5]. - Suzhou Polywin Biotechnology Co., Ltd. specializes in straw-based bio-manufacturing, presenting products such as bio-based 1,4-butanediamine and fully bio-based packaging materials [8]. - Ningbo Huafu New Materials Technology Co., Ltd. has developed a novel air oxidation route for producing FDCA, significantly reducing production costs and enhancing competitiveness [11][12]. - Henan Haosen Biological Materials Co., Ltd. has pioneered a continuous production process for bio-based 1,5-pentanediol using non-food biomass, achieving large-scale and efficient green production [15]. Group 3: Award Categories and Timeline - The award features four main categories: Innovation Material Award, Innovation Application Award, Most Commercially Valuable Award, and Innovative Industry Solution Award, likened to the "Oscars" of the bio-based industry [19]. - The first round of applications is open until February 10, 2026, with subsequent voting and evaluation phases scheduled for March 2026, culminating in an award ceremony on May 21, 2026 [27].

Core Viewpoint - The article discusses the shift in investment focus for the company from producing allulose and myo-inositol to developing high-end functional oils and nutritional health products due to declining investment value and increased competition in the allulose market [4][6][10]. Industry Trends - The biomanufacturing industry is experiencing a transformation, with a focus on enhancing key technological barriers and exploring differentiated products to overcome raw material cost challenges [2]. - The demand for high-end functional oils, particularly Omega-3 and ARA, is increasing in the Chinese market, driven by new standards for infant formula and a shift towards modern biomanufacturing techniques [8]. Company Actions - The company has announced a change in its fundraising projects, reallocating funds from the allulose and myo-inositol projects to new initiatives in oil and nutritional health products [4][6]. - The new projects include a 10,000-ton oil project and a smart factory for nutritional health products, with total planned investments of 25,708.54 million and 36,173.86 million respectively [5][9]. Financial Overview - The total planned investment for the new projects is 147,883.52 million, with 128,125.87 million expected to come from fundraising [5]. - The allulose and myo-inositol project had an original planned investment of 53,655.12 million, but was deemed less viable due to market conditions [6]. Project Details - The oil project aims to meet the growing demand for high-end functional oils and enhance China's market share in the international arena [7][8]. - The smart factory project will focus on creating a transparent and automated production system to improve product quality and traceability, enhancing competitiveness in the domestic market [9][10].

Core Viewpoint - The 11th Bio-based Conference and Exhibition will be held from May 20-22, 2026, in Shanghai, China, focusing on the latest achievements in the bio-based industry and the demands from the application side [1][17]. Group 1: Event Overview - The theme of the event is "Crossing New Cycles, Surging New Vitality," featuring 11 thematic forums, 7 concurrent activities, 1000 new product displays, and an innovation award ceremony [2][10]. - Over 50 sponsors have already confirmed their participation, including leading companies in the bio-based sector such as Evonik, Avantium, and others [2][3]. Group 2: Focus Areas - The exhibition will emphasize bio-based innovative materials and products in packaging, textiles, automotive, 3D printing, coatings, adhesives, and more [3][6]. - It aims to connect the supply and demand sides of the bio-based industry, focusing on the needs of downstream brand owners and facilitating strategic cooperation and procurement [6][7]. Group 3: Thematic Forums and Activities - The event will host 11 thematic forums covering key topics such as critical chemicals and materials, international cooperation, and bio-based applications in various industries [17][18]. - Seven concurrent activities will include a new product and technology release conference, a standard review meeting, and a high-level strategic seminar [18]. Group 4: Innovation and Awards - The 4th DT New Leaf Award will be held concurrently, recognizing innovations in materials, applications, commercial value, and industry solutions [19].

Core Insights - The article discusses the strategic investment by Qicai Chemical in Huanliang Technology, marking a significant step towards the industrialization of materials informatics and AI-driven research and development [2][3]. - Huanliang Technology aims to transform R&D into a reusable engineering system, moving from conceptual discussions to practical applications in industrial settings [3][4]. Investment and Collaboration - The partnership with Qicai Chemical, a publicly listed company, enhances the industrial synergy for the application of materials informatics, indicating a shift towards deliverable R&D efficiency rather than mere conceptual narratives [3][6]. - Huanliang Technology has attracted investments from notable firms like Sequoia and Baidu, establishing a robust resource network that supports platform iteration and industrial collaboration [3][6]. Team and Methodology - The core strength of Huanliang Technology lies in its interdisciplinary team, which combines scientific research with engineering practices, led by founder Liu Yuyang, who has extensive experience in theoretical physics and materials science [4][7]. - The company focuses on creating reproducible and traceable engineering processes in materials R&D, moving away from reliance on experiential methods [4][7]. Future Directions - Huanliang Technology plans to advance two main lines: one focusing on chemical processes and the other on functional materials, aiming to enhance efficiency in selection and iteration under small sample conditions [8]. - The collaboration with Qicai Chemical is seen as a key practice in empowering industrial upgrades through AI for Science, targeting core areas like organic pigments and new materials [8][10]. Efficiency Improvements - The partnership aims to reduce costs by optimizing reaction pathways and raw material ratios through Huanliang's Matcopilot® platform, leading to systematic reductions in R&D and production costs [9]. - The use of intelligent assistants is expected to significantly shorten R&D cycles from 1-2 years to 3-6 months, enhancing the speed of technology iteration and product commercialization [9]. - Huanliang's AI algorithms are designed to improve performance metrics, creating competitive advantages in high-end application scenarios [9][10]. Strategic Vision - The collaboration is positioned as a model for industry innovation and high-quality development, establishing a virtuous cycle of technology iteration, efficiency enhancement, and value creation [10]. - Huanliang Technology emphasizes measurable, verifiable, and deliverable R&D efficiency improvements while maintaining strict compliance and confidentiality regarding client data and processes [11].

Core Viewpoint - The article discusses the growing market for lactoferrin, particularly human-derived recombinant lactoferrin, highlighting its potential applications in infant formula and health supplements, as well as the challenges faced by companies in this sector [2][3][5]. Market Overview - The global market for lactoferrin is approximately $700 million, with an expected annual growth rate exceeding 7% [2]. - The primary application of lactoferrin is in infant formula, which accounts for nearly half of the total market share. Other applications include dietary supplements, pharmaceuticals, and functional foods [2]. - Japan is the largest market for lactoferrin, holding over 50% of the market share, followed by China, North America, and Europe, which collectively account for over 30% [2]. Company Insights - Beijing Guoke Xinglian Technology Co., Ltd. (Guoke Xinglian) is a leading company in the field of synthetic human active proteins, recently completing a financing round of over 100 million yuan to promote the industrialization and global marketing of its core functional protein/peptide products [2][3]. - Guoke Xinglian focuses on the innovative research of human homologous lactoferrin and utilizes microbial fermentation technology to produce functional human proteins, addressing key technological bottlenecks in the health and alternative protein sectors [3]. Technological Advancements - The preparation of human homologous lactoferrin is challenging due to the need to replicate its human glycosylation structure, which affects protein folding, stability, and functionality [4]. - Guoke Xinglian is the only company globally that uses food-grade yeast to express human homologous glycoproteins, positioning itself as a leader in the next generation of "human homologous" protein products [4][7]. Regulatory Landscape - Recombinant lactoferrin is accelerating its breakthrough through regulatory barriers, becoming a focal point in the global nutrition and health industry [7]. - As global regulatory frameworks improve, recombinant lactoferrin is transitioning from laboratory research to market availability, potentially reshaping the industry landscape for infant nutrition, immune therapy, and chronic disease management [7].

Core Viewpoint - The article emphasizes the importance of the Bio-based Young Scientists Forum as a platform for young researchers in the bio-based materials industry to showcase their innovations and connect with industry stakeholders, thereby enhancing their visibility and opportunities for collaboration [4][35]. Group 1: Importance of the Forum - The bio-based industry is experiencing explosive growth, with a reported increase of 29.8% in the first three quarters of 2025 and a monthly growth of 25.4% in November [9][10]. - Young researchers face a dilemma with a low funding success rate of 14-16% for national science projects, making it crucial to establish visibility in the industry [11][12]. - There is a significant gap in the commercialization of academic patents, with only 3.9% of university patents being industrialized compared to nearly 50% for enterprises, highlighting the need for better connections between academia and industry [14]. Group 2: Benefits of Participation - Participants will have a 10-minute platform to present their cutting-edge technologies, allowing for concise communication of their core innovations [15][16]. - The forum provides expert reviews and feedback from authoritative figures in the field, with awards for outstanding presentations, including a first prize of 2000 yuan [18][19]. - There will be real opportunities for industry connections, with over 1000 successful matches in the bio-based sector previously facilitated by the organizing company [20]. - Participants will receive dedicated promotional support, including custom posters and social media exposure, reaching over 200,000 individuals across various sectors [21][23]. Group 3: Target Audience - The forum is aimed at young scholars with research achievements in bio-based chemicals, materials, and additives, as their work may align with the needs of chemical companies undergoing transformation [26][28]. Group 4: Participation Details - The forum will take place on May 20, 2026, in Shanghai, as part of the 11th Bio-based Conference and Exhibition [30]. - Registration is straightforward, requiring participants to select the "Young Scientists Forum" option when signing up [31].

Core Viewpoint - The article discusses the development of a cost-effective biobased method for producing 3-hydroxypropanoic acid (3-HP) using genetically engineered microorganisms, highlighting its commercial potential and environmental benefits [2][3][5]. Group 1: Research and Development - Scientists from the University of Illinois and Penn State University have cultivated a high-yield strain of Issatchenkia orientalis for 3-HP production, confirming its commercial viability through technical economic analysis (TEA) and life cycle assessment (LCA) [3][5]. - The research team identified the β-alanine metabolic pathway as the optimal choice for maximizing 3-HP yield, with the lowest oxygen demand [5][6]. - The team achieved a 3-HP production yield of 29 g/L in shake flask fermentation and 92 g/L in fed-batch fermentation, surpassing previous commercial viability thresholds [6][8]. Group 2: Economic and Environmental Impact - The commercial potential of 3-HP is significant, with the acrylic acid market valued at approximately $20 billion and a global demand of about 6.6 million tons in 2019 [4]. - The estimated minimum product selling price (MPSP) for acrylic acid produced from pure glucose is $1.36/kg, which can be reduced to $1.13/kg when integrating the entire production chain with on-site corn dry milling [8]. - The carbon intensity of the corn-based route is 3.26 kg CO₂ equivalent/kg acrylic acid, which is lower than fossil-based acrylic acid in 98.5% of simulated scenarios [8][20]. Group 3: Future Directions - The research team plans to scale up the process, refine downstream operations, and incorporate other renewable feedstocks to enhance overall economic viability [9]. - CABBI researchers are exploring additional applications for 3-HP, such as its conversion into maleic acid and other high-value chemicals for use in vitamins, pharmaceuticals, biodegradable plastics, and agricultural chemicals [9].

使用蛋白质制造纤维的想法并不新鲜，但过去的尝试未能与合成材料竞争。 例如， Lanital 是20世纪30年代从牛奶蛋白中开发的一种材料， 当聚酯出现时，由于强度低而失宠。 最终， 早期的生物纤维(如来自花生和玉米蛋白的纤维)无法克服低性能和高成本的双重挑战，让廉价、坚固的聚酯占据了市场。 在这项新的研究中， 蛋白质从酵母中提取出来，溶解在溶剂中 ，并通过 喷丝头 形成连续纤维，然后纺成纱线。 /DT 生物基纺织鞋服 交流群/ 让专业的人聚在一起, 生物基纤维/纺织印染/品牌终端等产业同行❤️↓ 【SynBioCon】 获 悉，一项新的研究表明，可以用生产啤酒、葡萄酒或药品后剩下的废酵母来制造结实的服装纤维。 酒精和药物生产后剩余的酵母生物质由蛋白质、脂肪和糖等元素组成，通常被归类为副产品或废物。 美国宾夕法尼亚州立大学的研究人员从这种废料 中开发出了一种可持续的蛋白质纤 维 。 据报道，由此产生的纤维比天然纤维更坚固，每公斤的生产成本为6美元或更低(相比之下，羊毛的生产成本为10-12美元)。 有趣的是，它有可能解决世界饥饿和快时尚对环境的影响。 从废酵母中提取出来的 蛋白质纤维 关键词 | 绿色化工和新材 ...